Welcome to our dedicated page for Catalyst Crew Technologies SEC filings (Ticker: CCTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Catalyst Crew Technologies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Catalyst Crew Technologies's regulatory disclosures and financial reporting.
LataMed AI Corp. reported a net loss of $52,813 for the quarter ended March 31, 2026, with no revenue, as it shifted toward AI-enabled healthcare technology and services in Latin America. The company recorded intangible assets of $7,824,000, primarily from an asset purchase paid in shares, but reported no cash.
Current liabilities were $683,673, resulting in a working capital deficit of the same amount and an accumulated deficit of $29,653,599. Management disclosed that these conditions raise substantial doubt about its ability to continue as a going concern and is relying on 10% promissory notes and other financing to fund operations. Disclosure controls were deemed not effective due to limited internal resources.
LataMed AI Corp. notified the SEC that it cannot file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 within the prescribed time and expects to file within the five-calendar-day extension permitted by Rule 12b-25. The notification was signed by CEO Kevin Rodan Levy on May 15, 2026.
LATAMED AI CORP. adopted a new class of preferred stock called Series C Voting Preferred Stock through a Certificate of Designation filed in Nevada. The series authorizes 5,000,000 shares that are non-convertible, non-redeemable and entitled to dividends when declared, subject to senior securities.
Each Series C share carries twenty votes and votes together with common stock as a single class, while having a liquidation preference senior to common stock and equal to other preferred series unless otherwise stated. The series also includes protective provisions requiring Series C majority approval for key corporate actions and requires any merger or similar transaction to assume these rights.
LataMed AI Corp., formerly Catalyst Crew Technologies Corp., has formally changed its corporate name. On April 28, 2026, the company filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State to change its name to LataMed AI Corp.
The amendment became effective upon filing on April 28, 2026 and, according to the disclosure, the sole change was the new corporate name; all other provisions of the Articles of Incorporation remain unchanged. The Certificate of Amendment is included as Exhibit 3.1 to the report.
Catalyst Crew Technologies Corp. filed an amended annual report to update non-financial disclosures, including business description, risk factors, cybersecurity, properties, ownership, and related-party transactions, without changing its audited financial statements.
The company is a development-stage AI healthcare technology business focused on analytics and technology-enabled service coordination, has generated no revenue, and reported a 2025 net loss of $207,485 with an accumulated deficit of $29,600,786. As of December 31, 2025 it had no assets, current liabilities of $630,860, and its auditor expressed substantial doubt about its ability to continue as a going concern.
The filing details a February 2026 change in control, under which Dr. Kevin Rodan Levy became majority shareholder and sole director, contributed AI healthcare intellectual property for 12,000,000 shares, and shifted the company’s strategy toward Latin American healthcare markets through a Venezuelan subsidiary.
Catalyst Crew Technologies Corp. is a development-stage company building facial recognition software and reported no revenue for 2025 or 2024. For the year ended December 31, 2025, it recorded a net loss of $207,485, compared with a loss of $3,261,038 in 2024.
The balance sheet is extremely weak: as of December 31, 2025 the company reported no assets or cash and total liabilities of $630,860, resulting in a stockholders’ deficit of the same amount. The auditor issued a going concern paragraph, citing recurring losses, a large accumulated deficit of $29,600,786, and dependence on external financing.
The business has not commercialized its facial recognition technology and remains focused on research and development, funded by equity sales and notes payable. In February 2026, Dr. Kevin Rodan Levy acquired and was issued shares to reach 40,000,000 shares, or about 71.1% ownership, triggering a change in control and new leadership.
Catalyst Crew Technologies Corp. entered an Asset Purchase Agreement on February 17, 2026 with its CEO, Kevin Rodan Levy, to acquire assets for an artificial intelligence-enabled healthcare analytics platform, including CardioAI, PulmoAI, and NeuroAI intellectual property registered in Venezuela.
On March 23, 2026, the company acquired 100% of the shares of Inversiones Long 33, C.A., which became a wholly-owned Venezuelan subsidiary intended as its local operating entity within a broader Latin American strategy. On April 7, 2026, certain previously acquired intellectual property was assigned to this subsidiary as an internal reorganization step with no additional consideration.
The company also highlighted multiple press releases between March 23 and April 13, 2026 describing its operating structure, intellectual property assignments, and the introduction of its CardioAI, PulmoAI, and NeuroAI platforms.
Catalyst Crew Technologies Corp. appointed Carlos Peña as its new Chief Financial Officer, effective March 31, 2026. Peña, age 38, brings over ten years of experience in accounting, financial management, and audit support across several Venezuelan and international businesses.
The company reports no family relationships or related party transactions involving Peña, and notes that his appointment was not made under any prior arrangements. As of this report, there is no formal employment agreement in place and his compensation package has not yet been finalized.
Catalyst Crew Technologies Corp. filed a Form 12b-25 notification stating it cannot timely file its Annual Report on Form 10-K for the period ended December 31, 2025 due to delays in compiling and reviewing certain information required to finalize the financial statements. The company expects to file within the 15 calendar day extension period permitted under Rule 12b-25. The notification is signed by Kevin Rodan Levy, Chief Executive Officer, and dated March 31, 2026.
Catalyst Crew Technologies Corp. completed a transformational deal and change in control, shifting from an inactive shell to a development-stage digital health and artificial intelligence healthcare analytics company. The company acquired AI-enabled analytics and telehealth-related assets from its new CEO, Dr. Kevin Rodan Levy, in exchange for 12,000,000 restricted common shares.
Dr. Levy also purchased 28,000,000 existing shares for $10,000 in cash, giving him beneficial ownership of about 40,000,000 shares, or roughly 71.1% of the 56,296,895 common shares outstanding. All prior directors and officers resigned, and Dr. Levy became sole director and officer. The business remains pre-revenue, requires substantial additional capital, holds key patents only in Venezuela, and faces significant regulatory, competitive, and going concern risks as it tries to build and commercialize its AI and telehealth platforms, initially targeting Latin American markets.